The global Adalimumab Biosimilars market was valued at US$ 23200 million in 2023 and is anticipated to reach US$ 30870 million by 2030, witnessing a CAGR of 4.0% during the forecast period 2024-2030.

Adalimumab Biosimilars Market

Adalimumab, as a fully human anti-tumor necrosis factor alpha (TNF-ɑ) monoclonal antibody, can specifically bind to soluble human TNF-ɑ and block its interaction with cell surface TNF receptors p55 and p75. Thereby effectively blocking the inflammatory effect of TNF-ɑ.

North American market for Adalimumab Biosimilars is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Adalimumab Biosimilars is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global manufacturers of Adalimumab Biosimilars include Biotech, Hisun Pharmaceutical, Innovent Biologics, Fuhong Hanlin, China Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, China Cell Engineering, Suzhou Zhonghe Biomedical Technology and Amgen, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Adalimumab Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adalimumab Biosimilars.

Report Scope

The Adalimumab Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Adalimumab Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Adalimumab Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Adalimumab Biosimilars Market Report

Report Metric	Details
Report Name	Adalimumab Biosimilars Market
Accounted market size in 2023	US$ 23200 million
Forecasted market size in 2030	US$ 30870 million
CAGR	4.0%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	80mg 40mg 20mg
Segment by Application	Adult Child
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Biotech, Hisun Pharmaceutical, Innovent Biologics, Fuhong Hanlin, China Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, China Cell Engineering, Suzhou Zhonghe Biomedical Technology, Amgen, Sandoz, Boehringer Ingelheim, Mylan, Biogen
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Adalimumab Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Adalimumab Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Adalimumab Biosimilars Market growing?

Ans: The Adalimumab Biosimilars Market witnessing a CAGR of 4.0% during the forecast period 2024-2030.

What is the Adalimumab Biosimilars Market size in 2030?

Ans: The Adalimumab Biosimilars Market size in 2030 will be US$ 30870 million.

Who are the main players in the Adalimumab Biosimilars Market report?

Ans: The main players in the Adalimumab Biosimilars Market are Biotech, Hisun Pharmaceutical, Innovent Biologics, Fuhong Hanlin, China Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, China Cell Engineering, Suzhou Zhonghe Biomedical Technology, Amgen, Sandoz, Boehringer Ingelheim, Mylan, Biogen

What are the Application segmentation covered in the Adalimumab Biosimilars Market report?

Ans: The Applications covered in the Adalimumab Biosimilars Market report are Adult, Child

What are the Type segmentation covered in the Adalimumab Biosimilars Market report?

Ans: The Types covered in the Adalimumab Biosimilars Market report are 80mg, 40mg, 20mg

1 Adalimumab Biosimilars Market Overview

1.1 Product Overview and Scope of Adalimumab Biosimilars

1.2 Adalimumab Biosimilars Segment by Type

1.2.1 Global Adalimumab Biosimilars Market Value Comparison by Type (2024-2030)

1.2.2 80mg

1.2.3 40mg

1.2.4 20mg

1.3 Adalimumab Biosimilars Segment by Application

1.3.1 Global Adalimumab Biosimilars Market Value by Application: (2024-2030)

1.3.2 Adult

1.3.3 Child

1.4 Global Adalimumab Biosimilars Market Size Estimates and Forecasts

1.4.1 Global Adalimumab Biosimilars Revenue 2019-2030

1.4.2 Global Adalimumab Biosimilars Sales 2019-2030

1.4.3 Global Adalimumab Biosimilars Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Adalimumab Biosimilars Market Competition by Manufacturers

2.1 Global Adalimumab Biosimilars Sales Market Share by Manufacturers (2019-2024)

2.2 Global Adalimumab Biosimilars Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Adalimumab Biosimilars Average Price by Manufacturers (2019-2024)

2.4 Global Adalimumab Biosimilars Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Adalimumab Biosimilars, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Adalimumab Biosimilars, Product Type & Application

2.7 Adalimumab Biosimilars Market Competitive Situation and Trends

2.7.1 Adalimumab Biosimilars Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Adalimumab Biosimilars Players Market Share by Revenue

2.7.3 Global Adalimumab Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Adalimumab Biosimilars Retrospective Market Scenario by Region

3.1 Global Adalimumab Biosimilars Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Adalimumab Biosimilars Global Adalimumab Biosimilars Sales by Region: 2019-2030

3.2.1 Global Adalimumab Biosimilars Sales by Region: 2019-2024

3.2.2 Global Adalimumab Biosimilars Sales by Region: 2025-2030

3.3 Global Adalimumab Biosimilars Global Adalimumab Biosimilars Revenue by Region: 2019-2030

3.3.1 Global Adalimumab Biosimilars Revenue by Region: 2019-2024

3.3.2 Global Adalimumab Biosimilars Revenue by Region: 2025-2030

3.4 North America Adalimumab Biosimilars Market Facts & Figures by Country

3.4.1 North America Adalimumab Biosimilars Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Adalimumab Biosimilars Sales by Country (2019-2030)

3.4.3 North America Adalimumab Biosimilars Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Adalimumab Biosimilars Market Facts & Figures by Country

3.5.1 Europe Adalimumab Biosimilars Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Adalimumab Biosimilars Sales by Country (2019-2030)

3.5.3 Europe Adalimumab Biosimilars Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Adalimumab Biosimilars Market Facts & Figures by Country

3.6.1 Asia Pacific Adalimumab Biosimilars Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Adalimumab Biosimilars Sales by Country (2019-2030)

3.6.3 Asia Pacific Adalimumab Biosimilars Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Adalimumab Biosimilars Market Facts & Figures by Country

3.7.1 Latin America Adalimumab Biosimilars Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Adalimumab Biosimilars Sales by Country (2019-2030)

3.7.3 Latin America Adalimumab Biosimilars Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Adalimumab Biosimilars Market Facts & Figures by Country

3.8.1 Middle East and Africa Adalimumab Biosimilars Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Adalimumab Biosimilars Sales by Country (2019-2030)

3.8.3 Middle East and Africa Adalimumab Biosimilars Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Adalimumab Biosimilars Sales by Type (2019-2030)

4.1.1 Global Adalimumab Biosimilars Sales by Type (2019-2024)

4.1.2 Global Adalimumab Biosimilars Sales by Type (2025-2030)

4.1.3 Global Adalimumab Biosimilars Sales Market Share by Type (2019-2030)

4.2 Global Adalimumab Biosimilars Revenue by Type (2019-2030)

4.2.1 Global Adalimumab Biosimilars Revenue by Type (2019-2024)

4.2.2 Global Adalimumab Biosimilars Revenue by Type (2025-2030)

4.2.3 Global Adalimumab Biosimilars Revenue Market Share by Type (2019-2030)

4.3 Global Adalimumab Biosimilars Price by Type (2019-2030)

5 Segment by Application

5.1 Global Adalimumab Biosimilars Sales by Application (2019-2030)

5.1.1 Global Adalimumab Biosimilars Sales by Application (2019-2024)

5.1.2 Global Adalimumab Biosimilars Sales by Application (2025-2030)

5.1.3 Global Adalimumab Biosimilars Sales Market Share by Application (2019-2030)

5.2 Global Adalimumab Biosimilars Revenue by Application (2019-2030)

5.2.1 Global Adalimumab Biosimilars Revenue by Application (2019-2024)

5.2.2 Global Adalimumab Biosimilars Revenue by Application (2025-2030)

5.2.3 Global Adalimumab Biosimilars Revenue Market Share by Application (2019-2030)

5.3 Global Adalimumab Biosimilars Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Biotech

6.1.1 Biotech Corporation Information

6.1.2 Biotech Description and Business Overview

6.1.3 Biotech Adalimumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Biotech Adalimumab Biosimilars Product Portfolio

6.1.5 Biotech Recent Developments/Updates

6.2 Hisun Pharmaceutical

6.2.1 Hisun Pharmaceutical Corporation Information

6.2.2 Hisun Pharmaceutical Description and Business Overview

6.2.3 Hisun Pharmaceutical Adalimumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Hisun Pharmaceutical Adalimumab Biosimilars Product Portfolio

6.2.5 Hisun Pharmaceutical Recent Developments/Updates

6.3 Innovent Biologics

6.3.1 Innovent Biologics Corporation Information

6.3.2 Innovent Biologics Description and Business Overview

6.3.3 Innovent Biologics Adalimumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Innovent Biologics Adalimumab Biosimilars Product Portfolio

6.3.5 Innovent Biologics Recent Developments/Updates

6.4 Fuhong Hanlin

6.4.1 Fuhong Hanlin Corporation Information

6.4.2 Fuhong Hanlin Description and Business Overview

6.4.3 Fuhong Hanlin Adalimumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Fuhong Hanlin Adalimumab Biosimilars Product Portfolio

6.4.5 Fuhong Hanlin Recent Developments/Updates

6.5 China Biopharmaceuticals

6.5.1 China Biopharmaceuticals Corporation Information

6.5.2 China Biopharmaceuticals Description and Business Overview

6.5.3 China Biopharmaceuticals Adalimumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

6.5.4 China Biopharmaceuticals Adalimumab Biosimilars Product Portfolio

6.5.5 China Biopharmaceuticals Recent Developments/Updates

6.6 Chia Tai Tianqing Pharmaceutical Group

6.6.1 Chia Tai Tianqing Pharmaceutical Group Corporation Information

6.6.2 Chia Tai Tianqing Pharmaceutical Group Description and Business Overview

6.6.3 Chia Tai Tianqing Pharmaceutical Group Adalimumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Chia Tai Tianqing Pharmaceutical Group Adalimumab Biosimilars Product Portfolio

6.6.5 Chia Tai Tianqing Pharmaceutical Group Recent Developments/Updates

6.7 China Cell Engineering

6.6.1 China Cell Engineering Corporation Information

6.6.2 China Cell Engineering Description and Business Overview

6.6.3 China Cell Engineering Adalimumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

6.4.4 China Cell Engineering Adalimumab Biosimilars Product Portfolio

6.7.5 China Cell Engineering Recent Developments/Updates

6.8 Suzhou Zhonghe Biomedical Technology

6.8.1 Suzhou Zhonghe Biomedical Technology Corporation Information

6.8.2 Suzhou Zhonghe Biomedical Technology Description and Business Overview

6.8.3 Suzhou Zhonghe Biomedical Technology Adalimumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Suzhou Zhonghe Biomedical Technology Adalimumab Biosimilars Product Portfolio

6.8.5 Suzhou Zhonghe Biomedical Technology Recent Developments/Updates

6.9 Amgen

6.9.1 Amgen Corporation Information

6.9.2 Amgen Description and Business Overview

6.9.3 Amgen Adalimumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Amgen Adalimumab Biosimilars Product Portfolio

6.9.5 Amgen Recent Developments/Updates

6.10 Sandoz

6.10.1 Sandoz Corporation Information

6.10.2 Sandoz Description and Business Overview

6.10.3 Sandoz Adalimumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Sandoz Adalimumab Biosimilars Product Portfolio

6.10.5 Sandoz Recent Developments/Updates

6.11 Boehringer Ingelheim

6.11.1 Boehringer Ingelheim Corporation Information

6.11.2 Boehringer Ingelheim Adalimumab Biosimilars Description and Business Overview

6.11.3 Boehringer Ingelheim Adalimumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

6.11.4 Boehringer Ingelheim Adalimumab Biosimilars Product Portfolio

6.11.5 Boehringer Ingelheim Recent Developments/Updates

6.12 Mylan

6.12.1 Mylan Corporation Information

6.12.2 Mylan Adalimumab Biosimilars Description and Business Overview

6.12.3 Mylan Adalimumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

6.12.4 Mylan Adalimumab Biosimilars Product Portfolio

6.12.5 Mylan Recent Developments/Updates

6.13 Biogen

6.13.1 Biogen Corporation Information

6.13.2 Biogen Adalimumab Biosimilars Description and Business Overview

6.13.3 Biogen Adalimumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

6.13.4 Biogen Adalimumab Biosimilars Product Portfolio

6.13.5 Biogen Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Adalimumab Biosimilars Industry Chain Analysis

7.2 Adalimumab Biosimilars Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Adalimumab Biosimilars Production Mode & Process

7.4 Adalimumab Biosimilars Sales and Marketing

7.4.1 Adalimumab Biosimilars Sales Channels

7.4.2 Adalimumab Biosimilars Distributors

7.5 Adalimumab Biosimilars Customers

8 Adalimumab Biosimilars Market Dynamics

8.1 Adalimumab Biosimilars Industry Trends

8.2 Adalimumab Biosimilars Market Drivers

8.3 Adalimumab Biosimilars Market Challenges

8.4 Adalimumab Biosimilars Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Chia Tai Tianqing Pharmaceutical Group

China Biopharmaceuticals

China Cell Engineering

Suzhou Zhonghe Biomedical Technology

Amgen Inc

List of Tables

Table 1. Global Adalimumab Biosimilars Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Adalimumab Biosimilars Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Adalimumab Biosimilars Market Competitive Situation by Manufacturers in 2023

Table 4. Global Adalimumab Biosimilars Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Adalimumab Biosimilars Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Adalimumab Biosimilars Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Adalimumab Biosimilars Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Adalimumab Biosimilars Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Adalimumab Biosimilars, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Adalimumab Biosimilars, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Adalimumab Biosimilars, Product Type & Application

Table 12. Global Key Manufacturers of Adalimumab Biosimilars, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Adalimumab Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adalimumab Biosimilars as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Adalimumab Biosimilars Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Adalimumab Biosimilars Sales by Region (2019-2024) & (K Units)

Table 18. Global Adalimumab Biosimilars Sales Market Share by Region (2019-2024)

Table 19. Global Adalimumab Biosimilars Sales by Region (2025-2030) & (K Units)

Table 20. Global Adalimumab Biosimilars Sales Market Share by Region (2025-2030)

Table 21. Global Adalimumab Biosimilars Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Adalimumab Biosimilars Revenue Market Share by Region (2019-2024)

Table 23. Global Adalimumab Biosimilars Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Adalimumab Biosimilars Revenue Market Share by Region (2025-2030)

Table 25. North America Adalimumab Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Adalimumab Biosimilars Sales by Country (2019-2024) & (K Units)

Table 27. North America Adalimumab Biosimilars Sales by Country (2025-2030) & (K Units)

Table 28. North America Adalimumab Biosimilars Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Adalimumab Biosimilars Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Adalimumab Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Adalimumab Biosimilars Sales by Country (2019-2024) & (K Units)

Table 32. Europe Adalimumab Biosimilars Sales by Country (2025-2030) & (K Units)

Table 33. Europe Adalimumab Biosimilars Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Adalimumab Biosimilars Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Adalimumab Biosimilars Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Adalimumab Biosimilars Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Adalimumab Biosimilars Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Adalimumab Biosimilars Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Adalimumab Biosimilars Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Adalimumab Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Adalimumab Biosimilars Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Adalimumab Biosimilars Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Adalimumab Biosimilars Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Adalimumab Biosimilars Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Adalimumab Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Adalimumab Biosimilars Sales by Country (2019-2024) & (K Units)

Table 47. Middle East & Africa Adalimumab Biosimilars Sales by Country (2025-2030) & (K Units)

Table 48. Middle East & Africa Adalimumab Biosimilars Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Adalimumab Biosimilars Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Adalimumab Biosimilars Sales (K Units) by Type (2019-2024)

Table 51. Global Adalimumab Biosimilars Sales (K Units) by Type (2025-2030)

Table 52. Global Adalimumab Biosimilars Sales Market Share by Type (2019-2024)

Table 53. Global Adalimumab Biosimilars Sales Market Share by Type (2025-2030)

Table 54. Global Adalimumab Biosimilars Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Adalimumab Biosimilars Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Adalimumab Biosimilars Revenue Market Share by Type (2019-2024)

Table 57. Global Adalimumab Biosimilars Revenue Market Share by Type (2025-2030)

Table 58. Global Adalimumab Biosimilars Price (US$/Unit) by Type (2019-2024)

Table 59. Global Adalimumab Biosimilars Price (US$/Unit) by Type (2025-2030)

Table 60. Global Adalimumab Biosimilars Sales (K Units) by Application (2019-2024)

Table 61. Global Adalimumab Biosimilars Sales (K Units) by Application (2025-2030)

Table 62. Global Adalimumab Biosimilars Sales Market Share by Application (2019-2024)

Table 63. Global Adalimumab Biosimilars Sales Market Share by Application (2025-2030)

Table 64. Global Adalimumab Biosimilars Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Adalimumab Biosimilars Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Adalimumab Biosimilars Revenue Market Share by Application (2019-2024)

Table 67. Global Adalimumab Biosimilars Revenue Market Share by Application (2025-2030)

Table 68. Global Adalimumab Biosimilars Price (US$/Unit) by Application (2019-2024)

Table 69. Global Adalimumab Biosimilars Price (US$/Unit) by Application (2025-2030)

Table 70. Biotech Corporation Information

Table 71. Biotech Description and Business Overview

Table 72. Biotech Adalimumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Biotech Adalimumab Biosimilars Product

Table 74. Biotech Recent Developments/Updates

Table 75. Hisun Pharmaceutical Corporation Information

Table 76. Hisun Pharmaceutical Description and Business Overview

Table 77. Hisun Pharmaceutical Adalimumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. Hisun Pharmaceutical Adalimumab Biosimilars Product

Table 79. Hisun Pharmaceutical Recent Developments/Updates

Table 80. Innovent Biologics Corporation Information

Table 81. Innovent Biologics Description and Business Overview

Table 82. Innovent Biologics Adalimumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Innovent Biologics Adalimumab Biosimilars Product

Table 84. Innovent Biologics Recent Developments/Updates

Table 85. Fuhong Hanlin Corporation Information

Table 86. Fuhong Hanlin Description and Business Overview

Table 87. Fuhong Hanlin Adalimumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Fuhong Hanlin Adalimumab Biosimilars Product

Table 89. Fuhong Hanlin Recent Developments/Updates

Table 90. China Biopharmaceuticals Corporation Information

Table 91. China Biopharmaceuticals Description and Business Overview

Table 92. China Biopharmaceuticals Adalimumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. China Biopharmaceuticals Adalimumab Biosimilars Product

Table 94. China Biopharmaceuticals Recent Developments/Updates

Table 95. Chia Tai Tianqing Pharmaceutical Group Corporation Information

Table 96. Chia Tai Tianqing Pharmaceutical Group Description and Business Overview

Table 97. Chia Tai Tianqing Pharmaceutical Group Adalimumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Chia Tai Tianqing Pharmaceutical Group Adalimumab Biosimilars Product

Table 99. Chia Tai Tianqing Pharmaceutical Group Recent Developments/Updates

Table 100. China Cell Engineering Corporation Information

Table 101. China Cell Engineering Description and Business Overview

Table 102. China Cell Engineering Adalimumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. China Cell Engineering Adalimumab Biosimilars Product

Table 104. China Cell Engineering Recent Developments/Updates

Table 105. Suzhou Zhonghe Biomedical Technology Corporation Information

Table 106. Suzhou Zhonghe Biomedical Technology Description and Business Overview

Table 107. Suzhou Zhonghe Biomedical Technology Adalimumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. Suzhou Zhonghe Biomedical Technology Adalimumab Biosimilars Product

Table 109. Suzhou Zhonghe Biomedical Technology Recent Developments/Updates

Table 110. Amgen Corporation Information

Table 111. Amgen Description and Business Overview

Table 112. Amgen Adalimumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. Amgen Adalimumab Biosimilars Product

Table 114. Amgen Recent Developments/Updates

Table 115. Sandoz Corporation Information

Table 116. Sandoz Description and Business Overview

Table 117. Sandoz Adalimumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 118. Sandoz Adalimumab Biosimilars Product

Table 119. Sandoz Recent Developments/Updates

Table 120. Boehringer Ingelheim Corporation Information

Table 121. Boehringer Ingelheim Description and Business Overview

Table 122. Boehringer Ingelheim Adalimumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 123. Boehringer Ingelheim Adalimumab Biosimilars Product

Table 124. Boehringer Ingelheim Recent Developments/Updates

Table 125. Mylan Corporation Information

Table 126. Mylan Description and Business Overview

Table 127. Mylan Adalimumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 128. Mylan Adalimumab Biosimilars Product

Table 129. Mylan Recent Developments/Updates

Table 130. Biogen Corporation Information

Table 131. Biogen Description and Business Overview

Table 132. Biogen Adalimumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 133. Biogen Adalimumab Biosimilars Product

Table 134. Biogen Recent Developments/Updates

Table 135. Key Raw Materials Lists

Table 136. Raw Materials Key Suppliers Lists

Table 137. Adalimumab Biosimilars Distributors List

Table 138. Adalimumab Biosimilars Customers List

Table 139. Adalimumab Biosimilars Market Trends

Table 140. Adalimumab Biosimilars Market Drivers

Table 141. Adalimumab Biosimilars Market Challenges

Table 142. Adalimumab Biosimilars Market Restraints

Table 143. Research Programs/Design for This Report

Table 144. Key Data Information from Secondary Sources

Table 145. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Adalimumab Biosimilars

Figure 2. Global Adalimumab Biosimilars Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Adalimumab Biosimilars Market Share by Type in 2023 & 2030

Figure 4. 80mg Product Picture

Figure 5. 40mg Product Picture

Figure 6. 20mg Product Picture

Figure 7. Global Adalimumab Biosimilars Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 8. Global Adalimumab Biosimilars Market Share by Application in 2023 & 2030

Figure 9. Adult

Figure 10. Child

Figure 11. Global Adalimumab Biosimilars Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 12. Global Adalimumab Biosimilars Market Size (2019-2030) & (US$ Million)

Figure 13. Global Adalimumab Biosimilars Sales (2019-2030) & (K Units)

Figure 14. Global Adalimumab Biosimilars Average Price (US$/Unit) & (2019-2030)

Figure 15. Adalimumab Biosimilars Report Years Considered

Figure 16. Adalimumab Biosimilars Sales Share by Manufacturers in 2023

Figure 17. Global Adalimumab Biosimilars Revenue Share by Manufacturers in 2023

Figure 18. The Global 5 and 10 Largest Adalimumab Biosimilars Players: Market Share by Revenue in 2023

Figure 19. Adalimumab Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 20. Global Adalimumab Biosimilars Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 21. North America Adalimumab Biosimilars Sales Market Share by Country (2019-2030)

Figure 22. North America Adalimumab Biosimilars Revenue Market Share by Country (2019-2030)

Figure 23. United States Adalimumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 24. Canada Adalimumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 25. Europe Adalimumab Biosimilars Sales Market Share by Country (2019-2030)

Figure 26. Europe Adalimumab Biosimilars Revenue Market Share by Country (2019-2030)

Figure 27. Germany Adalimumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 28. France Adalimumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. U.K. Adalimumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. Italy Adalimumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Russia Adalimumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Asia Pacific Adalimumab Biosimilars Sales Market Share by Region (2019-2030)

Figure 33. Asia Pacific Adalimumab Biosimilars Revenue Market Share by Region (2019-2030)

Figure 34. China Adalimumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. Japan Adalimumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. South Korea Adalimumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. India Adalimumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. Australia Adalimumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. China Taiwan Adalimumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Southeast Asia Adalimumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Latin America Adalimumab Biosimilars Sales Market Share by Country (2019-2030)

Figure 42. Latin America Adalimumab Biosimilars Revenue Market Share by Country (2019-2030)

Figure 43. Mexico Adalimumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Brazil Adalimumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Argentina Adalimumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Middle East & Africa Adalimumab Biosimilars Sales Market Share by Country (2019-2030)

Figure 47. Middle East & Africa Adalimumab Biosimilars Revenue Market Share by Country (2019-2030)

Figure 48. Turkey Adalimumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Saudi Arabia Adalimumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. UAE Adalimumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. Global Sales Market Share of Adalimumab Biosimilars by Type (2019-2030)

Figure 52. Global Revenue Market Share of Adalimumab Biosimilars by Type (2019-2030)

Figure 53. Global Adalimumab Biosimilars Price (US$/Unit) by Type (2019-2030)

Figure 54. Global Sales Market Share of Adalimumab Biosimilars by Application (2019-2030)

Figure 55. Global Revenue Market Share of Adalimumab Biosimilars by Application (2019-2030)

Figure 56. Global Adalimumab Biosimilars Price (US$/Unit) by Application (2019-2030)

Figure 57. Adalimumab Biosimilars Value Chain

Figure 58. Adalimumab Biosimilars Production Process

Figure 59. Channels of Distribution (Direct Vs Distribution)

Figure 60. Distributors Profiles

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions